By Josh White
Date: Friday 25 Nov 2022
LONDON (ShareCast) - (Sharecast News) - Omega Diagnostics confirmed the receipt of deferred consideration from the sale of the CD4 business on Friday.
The AIM-traded medical diagnostics company said it had now received the £4m of deferred consideration.
"Accordingly, as of close-of-business on 24 November, Omega held cash balances of £6.5m," the board said in its short statement.
At 1116 GMT, shares in Omega Diagnostics Group were up 10.83% at 3.99p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
| Currency | UK Pounds |
| Share Price | 2.30p |
| Change Today | 0.35p |
| % Change | 17.95 % |
| 52 Week High | 4.00 |
| 52 Week Low | 1.95 |
| Volume | 1,148,016 |
| Shares Issued | 237.95m |
| Market Cap | £5.47m |
| Beta | 0.47 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:13 | 124,000 @ 2.32p |
| 15:12 | 552,995 @ 2.17p |
| 16:06 | 10,000 @ 2.31p |
| 16:03 | 435 @ 2.30p |
| 15:58 | 525 @ 2.30p |
You are here: research